induction was impaired in GC-resistant ALL cells and inhibition of mTORC1 using rapamycin restored GC sensitivity. However, GC-resistance was not ameliorated by stable ectopic expression of REDD1. Recently, REDD1 was implicated in GC-mediated mTORC1 inhibition in primary thymocytes and was reported to elicit a pro-survival response; however, whether this effect is cell autonomous was not determined. To further investigate the role of REDD1 in GC-treated thymocytes, primary thymocytes from wild-type and REDD1-deficient mice were characterized.
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Glucocorticoid hormones, which are produced by the adrenal cortex, affect a diverse number of cell types and physiological processes in the body, including development, brain function (cognition, memory, mood, etc.), energy metabolism, and immune response. In the immune system, glucocorticoids (GCs) attenuate immune activity, and are very effective and commonly prescribed anti-inflammatory drugs (1). GCs induce apoptotic cell death in a number of cell types, including T and B lymphocytes, and thymocytes represent one of the first reported examples of apoptosis (2) . For several decades now, GCs have been a mainstay component of treatment regimens for a variety of hematological malignancies, including leukemia and lymphoma (3, 4) . GC-induced apoptotic cell death in these cells requires the transactivation domain of the glucocorticoid receptor (5), a transcription factor of the nuclear hormone receptor family (6) seemingly expressed in every cell in the body, with the exception of non-nucleated red blood cells (7) . More recently it was reported that dexamethasone, a synthetic steroid hormone, can also induce autophagy in particular cell types, including lymphocytes (8) (9) (10) , and that autophagy may play a role in the GC-induced cell death resistance phenotype acquired by some cell types (9) .
The Redd1 gene (for Regulated in Development and DNA Damage Response 1) is highly conserved from flies to humans. It encodes a protein with no known structural or functional domains. A recent crystal structure revealed that REDD1 forms an α/β sandwich and identified a highly conserved surface that is required for activity and might interact with effector proteins (11) . Also known as DDIT4, Dig2, and RTP801, Redd1 was first identified in a screen for genes that are upregulated by hypoxia (12) , and was subsequently shown to be upregulated in response to a variety of other cellular stresses, including DNA damage, endoplasmic reticulum (ER) stress, and energy stress, as well as glucocorticoid treatment (13) (14) (15) (16) . Using microarray analysis, Wang et al. identified Dig2 (dexamethasone-induced gene 2) as a gene that was upregulated in murine T-cell lymphoma cell lines and primary thymocytes (16) . REDD1 is an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) (17-19), which integrates upstream inputs and responds by regulating cell growth and cell proliferation (20) . In most cell types examined, the hypoxia-induced inhibition of mTOR signaling requires REDD1 as well as the TSC1/TSC2
Redd1 -/-thymocytes undergo GC-induced cell death.
4 complex (17). However, this requirement is cell-type specific, as we found that REDD1 was not required for hypoxia-induced mTORC1 inhibition in hepatocytes (21).
CEM cell lines are established human T-cell acute lymphoblastic leukemia (ALL) cell lines that are commonly used to investigate molecular mechanisms and signaling pathways involved in GC-induced cell death. Resistance to GCs can arise in some patients undergoing long-term treatment with GCs, and analysis of GC-sensitive versus GC-resistant CEM cell lines is being exploited to investigate molecular differences that might play a role in the resistance phenotype (22-24). Interestingly, recent reports have shown that rapamycin, an mTORC1 inhibitor, can sensitize GC-resistant CEM cells to dexamethasone indicating that inhibiting mTORC1 signaling may be sufficient to bypass resistance (25, 26) . Inasmuch as REDD1 is induced by dexamethasone (27) (28) (29) and that forced overexpression of REDD1 is sufficient to inhibit mTORC1, we hypothesized that differential sensitivity of CEM cells to GCs may be dependent on REDD1.
Herein we sought to clarify the role of REDD1 in dexamethasone-induced cell death in CEM cells and primary thymocytes. While a recent report implicated a pro-survival role for Redd1 in glucocorticoid treated lymphocytes and primary thymocytes (27) , here we show that Redd1 ablation had no effect on GC-induced apoptosis in thymocytes. Additionally, overexpression of REDD1 in GCresistant ALL cells could not overcome the resistance phenotype. Our data demonstrate that REDD1 is neither necessary nor sufficient for GC-induced cell death.
Materials and Methods

Isolation and Treatment of Primary Thymocytes
Thymocytes were harvested as described in Wolff et al. (21) . Briefly, four-to six-week-old mice were sacrificed with an isofluorane overdose followed by cervical dislocation, and removal of the thymus.
Cells were dispersed with a pestle in a 1.5-ml tube in DMEM containing 10% FCS and 1% Pen-Strep.
After dilution in additional medium, cells were counted using a 1:1 TURKS solution (3% glacial acetic acid, 0.1% crystal violet in H 2 O) and plated at 2.5 x 10 6 cells/ml for experiments. Wild-type and
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Prime DNA labeling kit (Roche) and [α-32 P]dCTP according to the manufacturer's instructions.
Templates were generated by PCR using the following primers:
5' -TTATCGATGAGCGTGGTGGTTATGC (p114) and 3'-GCGCGTACATCGGGCAAATAATATC (p115) for ßgeo, 5'-CGGCTTCTGTGCGCCTTCAT (p125) and 3' -CTCCGGCCCGAAGCCACTGT (p126) for Redd1
(exon 2), 5' -ACTCCTCATACCTGGATGGGG (p127) and 3' -TTAACAGCCCCTGGATCTTG (p111)
for Redd1 (exon 3), 5' -AGGCCGTGATTCAGTACAGG (p611) and 3' -GAACGACTCTGAGGCTTTGG (P612) for
5' -TGCTCCTCCTGAGCGCAAGTACTC (p190) and 3'-CTCAGACCTGGGCCATTCAGAAAT for Actin.
Growth Curves
CEM, NAMALWA, and Raji cells were plated (at 4 x 10 5 cells/ml) in triplicate. At the indicated time points, the cells were resuspended, 50 μL removed for counting, and mixed with 50 μL of trypan blue solution. Cells were counted on a hemocytometer and both live and dead (trypan blue-positive) cells were scored.
Reagents
Antibodies against cleaved caspase 3 and REDD1 were from Bethyl. Antibodies against phosphorylated S6K (T389), phosphorylated S6 (S235/236), and phosphorylated 4E-BP1(T37/42) were from Cell Signaling. Antibody against tubulin was from Sigma. Anti-ß-galactosidase was from ICN.
Dexamethasone (Sigma-Aldrich) and rapamycin (LC Laboratories) were dissolved in methanol. Vehicle control was methanol. 
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Immunoblotting
Cells were washed in ice-cold PBS and lysed in ice-cold lysis buffer (50 mM Tris-HCl pH 7.4, 250 mM NaCl, 0.5% Igepal CA-630 containing protease (0.1 μM aprotinin, 0.02 mM leupeptin, 0.01 mM pepstatin, 0.5 mM benzamidine, 0.5 mM PMSF, 0.01 M NaF) and phosphatase (2 mM imidazole, 1.15 mM sodium molybdate, 1 mM sodium orthovanadate, 5 nM microcystin) inhibitors for 10 min. Lysates were cleared by centrifugation and protein concentration was measured using Bradford's method (Bio- 
REDD1 Overexpression
The C-terminal HA-tagged REDD1 construct (lab database plasmid #177) was generated as described previously (17). For retroviral transduction, Phoenix cells were transfected with control pBabe/HA (lab database plasmid #332) or pBabe/HA-REDD1 (Rd1-HA) (lab database plasmid #177) using Lipofectamine Plus (Invitrogen). Supernatant was collected and used to infect exponentially growing CEM, NAMALWA, and Raji cells following a "spinfection" protocol as follows. Cells were seeded at 2 x 10 6 cells/well in a 6-well dish in the presence of 2 ml viral supernatant, 4 μg/ml polybrene, and 0.5 ml FCS, spun at 2500 rpm (1,113 x g) for 1.5 hours at 37 o C. Cells were resuspended in fresh media (RPMI + 1x P/S+ 10% FCS) and incubated overnight. Spinfection protocol was repeated twice more and transduced cells were selected in media containing 2 μg/ml puromycin for 6 days. 
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Results
Two GC-sensitive (S) cell lines (CEM-C1-6 and CEM-C7-14) and one GC-resistant (R) cell line (CEM-C1-15) were treated with either vehicle control or 1 μM dexamethasone for up to 110 hours. Cells were harvested at different intervals for trypan blue exclusion to measure cell viability (Fig. 1A) , or trypan blue staining to measure nonviable cells (Fig. 1B) . As expected, the GC-sensitive CEM-C1-6 (S) and CEM-C7-14 (S) cells did not proliferate upon treatment with dexamethasone, while dexamethasonetreated GC-resistant CEM-C1-15 (R) cells grew at the same rate as vehicle-treated control cells (Fig. 1A) .
Cell death measurements were inversely correlated with these data, with the dexamethasone-treated CEM-C1-6 (S) and CEM-C7-14 (S) cells showing increased levels of cell death over time, while CEM-C1-15 (R) cells had very low levels of cell death upon dexamethasone treatment (Fig. 1B ).
Immunoblot analysis of protein lysates from these cells showed the expected increase in caspase 3 (indicative of increased apoptosis) in CEM-C1-6 (S) and CEM-C7-14 (S) cells. Next, we asked whether dexamethasone treatment had differential effects on mTORC1 in GC-sensitive versus GC-resistant cell lines. For these experiments, we evaluated the phosphorylation state of two substrates of mTORC1, S6K
and 4E-BP1, as well as ribosomal protein S6 (a substrate of S6K). Compared to vehicle treated samples, we observed a progressive inhibition of mTORC1 over time in both sensitive cell lines (Fig. 1C) .
Interestingly, no mTORC1 inhibition was detected in CEM-C1-15 (R) cells over the course of the experiment (Fig. 1C ). Thus, a correlation was observed between sensitivity to dexamethasone and mTORC1 inhibition. These data suggest that mTORC1 inhibition may contribute to dexamethasone sensitivity.
To determine whether mTORC1 inhibition was implicated in dexamethasone sensitization, we treated CEM-C1-15 (R) cells with rapamycin, an mTORC1 inhibitor. While dexamethasone alone failed to inhibit mTORC1 in these cells, mTORC1 was profoundly inhibited by treatment with rapamycin ( Fig 
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proliferation in a manner dependent on rapamycin concentration (Fig. 2B ), which is consistent with previous results (26, 33). (The lack of difference between the Dex+10 nM rapa and Dex+100 nM rapa is most likely due to the fact that cell viability is already greatly reduced in the Dex+10 nM rapa-treated cells.) In contrast, rapamycin alone inhibited cell proliferation to a much lesser extent (Fig. 2B) . Thus, despite that rapamycin by itself was sufficient to inhibit mTORC1 ( Fig. 2A) , the suppression of cell proliferation required both rapamycin and dexamethasone (Fig. 2B) . The suppression of cell proliferation by the rapamycin/dexamethasone combination was due, at least in part, to increased cell death (Fig. 2C ).
However, even at the highest rapamycin concentration used, cell death in CEM-C1-15 (R) cells was lower than in dexamethasone-treated CEM-C1-6 (S) cells (Fig. 2C ). Given the very profound effect of the combination treatment on cell proliferation ( Fig. 2B ), rapamycin may synergize with dexamethasone in more than one way.
Overall, these data show that mTORC1 inhibition can sensitize resistant ALL cells to dexamethasone. To obtain insight into the mechanism whereby mTORC1 is normally inhibited in response to dexamethasone, we evaluated REDD1 expression. REDD1 is induced by GCs (16, 27, 28) , and is sufficient to inhibit mTORC1 (17). In the two sensitive ALL cell lines, REDD1 expression was upregulated within a few hours and remained elevated throughout the time course (Fig. 1C) . REDD1 was also induced in resistant CEM-C1-15 (R), but to a lesser extent (Fig. 1C) . We hypothesized that lower levels of REDD1 may explain the lack of mTORC1 inhibition in dexamethasone-treated CEM-C1-15 (R) cells. We therefore asked whether, as for rapamycin, forced expression of REDD1 could overcome GC resistance in CEM-C1-15 (R) cells. CEM-C1-15 (R) cells were transduced with an HA-tagged REDD1
(or an empty vector control), and then treated with dexamethasone or vehicle (Fig. 3A) . We found that REDD1 overexpression did not sensitize the CEM-C1-15 (R) cells to dexamethasone, nor did it further sensitize the cells to rapamycin treatment (Fig. 3A) . These results might be explained by the fact that despite ectopic REDD1 overexpression, there was very little effect on mTORC1 inhibition, as evidenced by phospho-S6 levels ( Fig. 3B ). Overexpression of REDD1 is therefore not sufficient to overcome the GC-resistance phenotype of CEM-C1-15 (R) cells. 
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We next looked at whether higher levels of ectopic REDD1 expression might be achieved in other GC-resistant cell lines. The NAMALWA and Raji cell lines are human Burkitt's lymphoma cell lines that have been shown to be resistant to GC treatment-induced cell death (Fig. 3 , C and D) (33, 34) .
Similar to CEM-C1-15 (R) GC-resistant cells, these cell lines could also be sensitized to dexamethasoneinduced cell death by treatment with rapamycin (Fig. 3 , C and D) (26). We overexpressed HA-tagged REDD1 in these two cell lines. Modest levels of REDD1 expression were achieved (Fig. 3 , E and F), and neither the NAMALWA cells nor the Raji cells showed increased sensitivity to GC treatment upon REDD1 overexpression (Fig. 3, C and D) . Additionally, overexpression of REDD1 did not lead to increased inhibition of mTORC1 signaling upon GC treatment ( While experiments in the resistant cell lines show that REDD1 induction is not sufficient to cause cell death, it remains to be determined whether REDD1 induction is necessary for GC-mediated cell death in sensitive cells. For these experiments, CEM sensitive cell lines may be subjected to Redd1 depletion by shRNA, and exposed to dexamethasone. However, shRNA-mediated depletion is seldom complete, and despite the use of multiple shRNAs, confounding off-target effects can never be completely ruled out. For these reasons, we turned to a better experimental system. We chose to answer the question using primary thymocytes from wild-type and Redd1-deficient mice.
Primary thymocytes cells have long been known to be sensitive to GC treatment (35, 36), and it has been reported that REDD1 was upregulated in thymocytes in response to treatment with dexamethasone (27, 29) . We therefore decided to look at the role of REDD1 in primary thymocytes.
Primary thymocytes were harvested from 4-to 6-week-old mice and treated for 0, 5, or 10 hours with 1 μM dexamethasone, and then stained with PI and subjected to FACS to measure percentage of dead cells.
As expected, the percentage of PI-positive cells increased over time, demonstrating an increase in cell death upon dexamethasone treatment ( 
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requirement for new transcription, as well as by treatment with RU486, a GC receptor antagonist, demonstrating that ligand binding and activation through the GC receptor is also required (Fig. 4A ).
Dexamethasone treatment of primary thymocytes induced caspase 3 cleavage, and this could be blocked by treatment with ActD (Fig. 4B) . The induction of caspase 3 cleavage was paralleled by an induction of REDD1 and the inhibition of mTORC1 (Fig. 4B) . Expression of the canonical GC-response gene Fkbp5 (37) was blocked by ActD (Fig. 4C ). Redd1 induction (at both the mRNA and protein level), as well as mTORC1 inhibition, was also blocked by ActD (Fig. 4B and C inhibited dexamethasone-induced cell death (Fig. 5A ).
We next asked whether loss of Redd1 had an effect on GC-induced mTORC1 inhibition in thymocytes. Surprisingly, we found that loss of Redd1 did not affect mTORC1 inhibition by dexamethasone (Fig. 5B) . Overall, phospho-S6K and phospho-4E-BP1 levels were very similar in dexamethasone-treated Redd1 ßgeo/ßgeo thymocytes compared to wild-type (Fig. 5B) . Immunoblot analysis showed upregulation of REDD1 in wild-type cells upon dexamethasone treatment, and confirmed that the 
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REDD1(1-65)-β-galactosidase chimeric reporter protein, but not endogenous REDD1 protein, was expressed in the Redd1 ßgeo/ßgeo cells (Fig. 5B) . Cleaved caspase 3 levels were also similar between the wild-type and Redd1 ßgeo/ßgeo cells demonstrating similar levels of apoptosis (Fig. 4B) . Thus, these data show that Redd1 is dispensable for GC-induced cell death in thymocytes.
We reasoned that Redd1 might be dispensable because it is not necessary to inhibit mTORC1 in response to GC treatment, and asked whether mTORC1 inhibition alone would be sufficient to induce apoptosis in primary thymocytes. We found that rapamycin treatment alone did not induce cell death in either Redd1 ßgeo/ßgeo or wild-type thymocytes, nor did it abrogate or enhance the cell death induced by dexamethasone treatment (Fig. 6A ). Immunoblot analysis confirmed the upregulation of REDD1 in wildtype cells and the absence of endogenous REDD1 protein in the Redd1 ßgeo/ßgeo cells (Fig. 6B ). It also confirmed that rapamycin treatment effectively inhibited mTORC1 signaling as evidenced by the decrease in phospho-S6K levels (Fig. 6B ).
Discussion
Our lab has had a long-standing interest in Redd1 and its involvement in mTOR signaling. Here, using a variety of cell types, both tumor-derived and primary cells, we characterize the role of REDD1 and mTORC1 in GC-induced cell death. We show that Redd1 is neither necessary nor sufficient for dexamethasone-induced cell death. In addition, Redd1 is dispensable for mTORC1 inhibition by dexamethasone in thymocytes. However, whereas mTORC1 inhibition does not affect dexamethasoneinduced cell death in thymocytes, rapamycin, via its mTORC1 inhibitory action, or perhaps by other mechanisms, sensitizes glucocorticoid-resistant leukemia and lymphoma cells to dexamethasone-induced cell death.
Our results are consistent with the notion that GC resistance in leukemia and lymphoma cells may 
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expression of REDD1 was not enough. This may be explained by the modest levels of REDD1 expression in all three cell lines. These cell lines are difficult to manipulate and experiments were performed in stable cells in which REDD1 was constitutively expressed. Thus, it is possible that higher REDD1-expressing cells were not recovered because of lower fitness. This is consistent with the notion that rapamycin reduced, though not very significantly, the growth rates in CEM and Raji cells. Alternatively, REDD1 overexpression may not be sufficient to inhibit mTORC1 in these cell types. We have previously shown that REDD1-mediated mTORC1 inhibition is TSC1/TSC2-dependent (17), and disruption of this complex blocks REDD1 effects. Interestingly, REDD1 is constitutively upregulated in renal cancer, where it also fails to induce mTORC1 inhibition (38). Overall, these data reveal a cell context-dependency of REDD1-mediated inhibition of mTORC1. Understanding the determinants of permissiveness may shed insight into fundamental mechanisms of mTORC1 regulation and drug sensitivity.
REDD1 has been previously implicated as having a protective role against apoptosis. While focusing on the role of Redd1 in autophagy, Molitoris et al. reported that Redd1 null thymocytes have
increased apoptosis compared to wild-type thymocytes in response to dexamethasone treatment (27) .
These authors reported a 50% increase in thymocyte cell death in the absence of Redd1. However, our data show that the induction of Redd1 in dying cells undergoing apoptosis does not necessarily imply a role for REDD1 (protective or otherwise) in cell death. We show that Redd1 is induced in response to dexamethasone in primary thymocytes and that this treatment results in 80% cell death by 10 hours. This process is accompanied by the induction of Redd1 and requires de novo transcription (as established by ActD experiments). However, we found that REDD1 ablation has no effect on GC-induced cell death in primary thymocytes, and that levels of GC-induced apoptosis are the same in wild-type and Redd1 inhibition by dexamethasone. These data suggest that dexamethasone inhibits mTORC1 through, at least in part, Redd1-independent mechanisms. Inasmuch as the effect of dexamethasone can be blocked by ActD, the data are consistent with the notion that GCs induce several genes that inhibit mTORC1. As for Redd1, inactivation of this putative second mechanism may not be sufficient to restore mTORC1 in GCtreated cells, and simultaneous loss with Redd1 may be required.
It is interesting that rapamycin synergized with dexamethasone in the tumor-derived cell lines, but not in the primary thymocytes, and that rapamycin alone, while inhibiting the proliferation of tumor cells, had no effect on thymocyte apoptosis. However, primary thymocytes do not survive well in vitro and these experiments involved different assays. Thus, we cannot exclude that under conditions allowing the expansion of primary thymocytes in vitro, rapamycin may have similarly inhibited cell growth.
GC therapy is a common component in the chemotherapeutic treatment of hematological cancers, including lymphomas and leukemias, due to their ability to induce cell death in these cells. Yet, while
GCs are beneficial, they are also associated with undesirable side effects such as hyperglycemia, osteoporosis, cardiovascular disease, cataracts and glaucoma. A better understanding of the molecular mechanisms underlying GC action may help in designing novel, more efficacious, and less toxic analogues (39). While much has been learned about the downstream genes and pathways that mediate GC hormone-induced cell death, their precise mechanism of action is still not fully understood. Therefore, it is critical that the signaling pathways involved be fully investigated.
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empty vector control or an HA-tagged REDD1 cDNA were treated with vehicle control, 1 μM dexamethasone, 100 nM rapamycin, or 1 μM dexamethasone + 100 nM rapamycin for 100 hours. Cell growth/viability was measured by trypan blue staining. E and F) Immunoblot analysis of NAMALWA cells (E) and Raji cells (F) treated as in (C) and (D), respectively, to examine REDD1 protein expression, and phospho-S6K(T389), phospho-S6(S235/236), and tubulin (loading control) levels. 
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